Medical School · Year 2 · Immunology · includes a quiz and discussion video

Lecture 11: Vaccines and Immunopharmacology

Unit 2.7: Immunology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the principles of vaccination and herd immunity
2. Explain different vaccine types and their mechanisms
3. Describe the vaccine development and approval process
4. Explain immunomodulatory therapies
5. Describe the clinical use of cytokines and antibodies
6. Explain adverse reactions to immunotherapy

Lecture Outline

I. Principles of Vaccination

Vaccination represents one of the most impactful public health interventions in human history, preventing millions of deaths annually and enabling the eradication of smallpox, the only human disease ever eliminated through deliberate effort. The historical foundations of vaccination trace back to 1796 when Edward Jenner demonstrated that inoculation with cowpox protected against smallpox, establishing the principle that controlled exposure to a related or weakened pathogen could induce protective immunity. Louis Pasteur extended this concept in the 1880s by developing attenuated vaccines against anthrax and rabies. The twentieth century witnessed tremendous advances including Jonas Salk's inactivated polio vaccine in 1955 and Albert Sabin's oral live attenuated version, leading to the near-eradication of poliomyelitis. The COVID-19 pandemic catalyzed the remarkably rapid development and deployment of mRNA vaccines, representing a new paradigm in vaccinology that can be adapted to emerging pathogens with unprecedented speed.

The immunological basis of vaccination rests on the principle of immunological memory, the capacity of the adaptive immune system to mount faster and more robust responses upon re-encounter with a previously seen antigen. During primary vaccination, antigens from the vaccine are captured by dendritic cells and presented to naive T and B lymphocytes in lymphoid tissues. This leads to clonal expansion of antigen-specific lymphocytes, differentiation into effector cells that may contribute to clearing any concurrent infection, and critically, generation of long-lived memory T cells and memory B cells that persist for years to decades. Upon subsequent exposure to the actual pathogen, these memory cells rapidly reactivate, proliferate, and generate protective effector responses before the pathogen can cause disease. This secondary or anamnestic response is faster (days rather than weeks), more robust (higher magnitude), and more effective (higher affinity antibodies due to somatic hypermutation during the primary response) than the primary response would have been.

Correlates of protection are immunological measurements that predict vaccine-induced protection against disease. For many vaccines, neutralizing antibody titers serve as the primary correlate, with established thresholds indicating protective immunity. For example, an anti-HBsAg antibody level of 10 mIU/mL or greater is considered protective against hepatitis B, while anti-tetanus toxoid levels of 0.1 IU/mL indicate protection against tetanus. For other pathogens, cellular immunity may be the primary protective mechanism, though T cell responses are more difficult to measure routinely. Understanding correlates of protection is essential for vaccine development, licensure, and monitoring of population immunity. For some diseases, correlates remain incompletely defined, complicating vaccine evaluation. The concept of a threshold or "protective level" is a simplification; in reality, protection is often a continuum, with higher antibody levels conferring greater protection.

Herd immunity (or community immunity) describes the indirect protection conferred to susceptible individuals when a sufficient proportion of the population is immune to a pathogen, thereby reducing transmission. When immunity levels reach the herd immunity threshold, each infected individual transmits the pathogen to fewer than one susceptible person on average, causing outbreaks to wane rather than amplify. The threshold depends on the basic reproduction number (R0) of the pathogen, the average number of secondary infections caused by one infected individual in a fully susceptible population. Mathematically, the herd immunity threshold equals 1 minus 1/R0; for measles with R0 of 12-18, thresholds of 92-95% are required, while for polio with R0 of 5-7, thresholds are approximately 80-85%. Herd immunity protects individuals who cannot be vaccinated, including infants too young for certain vaccines, immunocompromised patients for whom live vaccines are contraindicated, and the small percentage of vaccinees who do not mount protective responses. Maintaining herd immunity requires sustained high vaccination coverage; declines in coverage, as seen with measles in some communities, lead to disease resurgence.

<image> Panel A: Vaccination history timeline showing key milestones: Jenner's cowpox vaccination (1796), Pasteur's rabies vaccine (1885), Salk inactivated polio vaccine (1955), smallpox eradication (1980), and COVID-19 mRNA vaccines (2020), with images representing each milestone and impact statistics (lives saved, diseases prevented). Panel B: Immunological memory mechanism showing primary vaccination leading to antigen uptake by DC, T and B cell activation, effector response, and generation of long-lived memory cells; then pathogen exposure triggering rapid memory cell reactivation with faster, higher-magnitude secondary response compared to theoretical primary response, depicted with antibody titer curves. Panel C: Correlates of protection examples showing antibody thresholds for different vaccines: hepatitis B (anti-HBs >10 mIU/mL), tetanus (anti-toxoid >0.1 IU/mL), measles (neutralizing Ab titer), with notation that cellular immunity is primary correlate for some pathogens (e.g., tuberculosis) but harder to measure. Panel D: Herd immunity concept illustration showing population grid with vaccinated (immune) and susceptible individuals, demonstrating how pathogen transmission is interrupted when sufficient proportion is immune; formula for herd immunity threshold (1 - 1/R0) with calculations for measles (R0=15, threshold=93%) and polio (R0=6, threshold=83%), and groups protected by herd immunity (infants, immunocompromised, vaccine non-responders). </image>

II. Types of Vaccines

Live attenuated vaccines contain pathogens that have been weakened through serial passage in culture, genetic modification, or other methods so that they can replicate in the host but do not cause disease in immunocompetent individuals. Because these vaccines undergo limited replication, they mimic natural infection and induce strong, durable immune responses typically with a single dose. Examples include the measles-mumps-rubella (MMR) vaccine, varicella vaccine, oral polio vaccine (OPV), rotavirus vaccine, and yellow fever vaccine. The major advantages are potent immunogenicity, long-lasting protection, and in some cases the ability to induce mucosal immunity through oral administration. However, live attenuated vaccines are contraindicated in immunocompromised patients and during pregnancy because the attenuated pathogen could potentially cause disease in these populations. Additionally, live vaccines may require cold chain maintenance for stability, and rarely, reversion to virulence can occur (as with vaccine-derived poliovirus from OPV).

Inactivated (killed) vaccines contain pathogens that have been rendered non-replicating through chemical treatment (typically formalin), heat, or irradiation while preserving immunogenic structures. Because these vaccines cannot replicate, they are generally safer than live vaccines and can be administered to immunocompromised patients. However, the absence of replication means that immune responses are typically weaker, requiring multiple doses and often adjuvants to achieve adequate immunogenicity. Examples include the inactivated polio vaccine (IPV), hepatitis A vaccine, rabies vaccine, and most influenza vaccines. Whole-cell inactivated vaccines contain all pathogen components and can be reactogenic; split or purified preparations reduce adverse reactions while maintaining key antigens. Inactivated vaccines primarily induce humoral (antibody) responses and may not generate robust mucosal or cellular immunity, depending on the specific vaccine and route of administration.

Subunit vaccines contain purified components of pathogens rather than whole organisms, reducing the potential for adverse reactions while focusing the immune response on key protective antigens. Recombinant subunit vaccines use genetically engineered systems (yeast, insect cells, mammalian cells) to produce large quantities of a specific antigen. The hepatitis B vaccine consists of recombinant hepatitis B surface antigen (HBsAg) produced in yeast, while the human papillomavirus (HPV) vaccine contains recombinant L1 capsid proteins that self-assemble into virus-like particles. Acellular pertussis vaccines contain purified Bordetella pertussis antigens (pertussis toxoid, filamentous hemagglutinin, pertactin) and have replaced more reactogenic whole-cell pertussis vaccines in many countries. Subunit vaccines typically require adjuvants to enhance immunogenicity and multiple doses to achieve protection.

Conjugate vaccines address the challenge that polysaccharide antigens, which form the capsules of many bacterial pathogens, are T-independent antigens that do not generate memory B cells or elicit robust responses in young children. By covalently linking the polysaccharide to a carrier protein (such as tetanus toxoid, diphtheria toxoid, or CRM197), the vaccine converts the polysaccharide into a T-dependent antigen capable of inducing T cell help, memory responses, and protective immunity in infants. Conjugate vaccines have been developed against Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (PCV13, PCV15, PCV20), and Neisseria meningitidis (serogroups A, C, W, Y). The introduction of Hib and pneumococcal conjugate vaccines has dramatically reduced invasive disease caused by these encapsulated bacteria, representing major public health achievements. Toxoid vaccines contain inactivated bacterial toxins (toxoids) that induce antibodies neutralizing the toxin; tetanus and diphtheria toxoids are the primary examples, requiring periodic boosters to maintain protective immunity.

<image> Panel A: Live attenuated vaccine concept showing pathogen attenuation through serial passage (depicted as virus passing through cell cultures with accumulated mutations), resulting in weakened virus that replicates but does not cause disease, inducing robust immune response similar to natural infection; examples (MMR, varicella, OPV, rotavirus, yellow fever) with advantages (potent immunity, often single dose) and contraindications (immunocompromised, pregnancy). Panel B: Inactivated vaccine comparison showing whole pathogen treated with formalin or heat to kill without destroying structure, with examples (IPV, hepatitis A, rabies, influenza) and characteristics (safer for immunocompromised, weaker response requiring multiple doses and adjuvants, primarily humoral immunity). Panel C: Subunit and recombinant vaccine production showing gene encoding antigen inserted into yeast expression vector, protein production and purification, assembly into vaccine (hepatitis B HBsAg, HPV virus-like particles), with advantages of focused immune response and reduced reactogenicity but need for adjuvants. Panel D: Conjugate vaccine mechanism showing polysaccharide alone as T-independent antigen (no T cell help, poor memory, poor infant response), then polysaccharide-protein conjugate engaging B cell through polysaccharide with T cell help from protein carrier, generating memory B cells; examples (Hib, PCV, meningococcal) with dramatic disease reduction graphs. </image>

III. Nucleic Acid and Viral Vector Vaccines

Messenger RNA (mRNA) vaccines represent a revolutionary platform that emerged into widespread clinical use during the COVID-19 pandemic. These vaccines deliver mRNA encoding the target antigen encapsulated in lipid nanoparticles that protect the nucleic acid from degradation and facilitate cellular uptake. Once inside host cells, the mRNA is translated by cellular ribosomes into the encoded antigen protein, which is then processed and presented on MHC molecules to induce T cell responses, while secreted or surface-displayed antigen triggers B cell activation and antibody production. Modified nucleosides incorporated into the mRNA reduce innate immune sensing and improve translation efficiency. The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines demonstrated remarkable efficacy exceeding 90% against symptomatic infection in initial trials and were administered to billions of people worldwide. Advantages of mRNA vaccines include rapid development and manufacturing (the sequence can be designed within days of pathogen identification), no risk of integration into the host genome, and the ability to induce both humoral and cellular immunity. Disadvantages include the requirement for ultra-cold storage (though newer formulations are more stable) and the typical need for multiple doses.

Viral vector vaccines use a harmless virus (the vector) to deliver genetic material encoding the target antigen into host cells. The vector virus is typically rendered replication-deficient to prevent uncontrolled spread while retaining the ability to infect cells and deliver its genetic payload. Adenovirus vectors are most commonly used, with the COVID-19 vaccines from Johnson & Johnson (Ad26 vector) and AstraZeneca/Oxford (chimpanzee adenovirus ChAdOx1) representing prominent examples. The Ebola vaccine rVSV-ZEBOV uses a vesicular stomatitis virus vector expressing Ebola glycoprotein. Once the vector infects host cells, the encoded antigen is expressed, processed, and presented to induce immune responses similar to natural infection. Viral vector vaccines typically induce strong immune responses, including cellular immunity, and may require only a single dose for some applications. However, pre-existing immunity to the vector virus (particularly human adenoviruses) can reduce vaccine efficacy, and rare but serious adverse events including vaccine-induced immune thrombocytopenia and thrombosis (VITT) have been associated with adenoviral vector COVID-19 vaccines.

DNA vaccines, while extensively studied in preclinical and clinical settings, have had limited human approvals to date. These vaccines deliver plasmid DNA encoding the target antigen, which must enter the cell nucleus for transcription into mRNA before translation into protein. Delivery methods include intramuscular injection, sometimes enhanced by electroporation to increase cellular uptake. DNA vaccines are highly stable, inexpensive to produce, and do not require cold chain, but have generally shown weaker immunogenicity in humans compared to other platforms. Several DNA vaccines have been approved for veterinary use, including against West Nile virus in horses and canine melanoma. Human DNA vaccines are in development for various infectious diseases and cancers.

Different vaccine platforms offer distinct advantages and trade-offs that inform their selection for specific applications. Live attenuated vaccines provide excellent immunogenicity mimicking natural infection but carry risks for immunocompromised individuals. Inactivated and subunit vaccines are safer but typically less immunogenic, requiring adjuvants and multiple doses. mRNA vaccines enable rapid design and manufacturing with excellent efficacy but require cold chain logistics. Viral vector vaccines induce strong responses, including cellular immunity, but face challenges from pre-existing vector immunity and rare safety signals. Heterologous prime-boost strategies, using different platforms for initial and subsequent doses, can potentially combine the advantages of multiple approaches and have shown enhanced immunogenicity in some settings, as demonstrated during COVID-19 vaccination programs that mixed viral vector and mRNA vaccines.

<image> Panel A: mRNA vaccine mechanism showing mRNA encoding spike protein encapsulated in lipid nanoparticle, cellular uptake and endosomal escape, ribosomal translation into spike protein, MHC presentation to T cells, and secreted/surface spike inducing B cell responses and antibody production; with advantages (rapid development, no integration risk, strong immunity) and cold storage requirement notation. Panel B: Viral vector vaccine mechanism showing replication-deficient adenovirus carrying spike gene, cell infection and nuclear entry, transcription and translation of spike protein, immune responses similar to natural infection; examples (J&J Ad26, AstraZeneca ChAdOx1, Ebola rVSV-ZEBOV) with pre-existing immunity consideration and VITT rare risk. Panel C: DNA vaccine concept showing plasmid DNA injected intramuscularly, uptake into cell nucleus, transcription to mRNA, translation to protein, immune response generation; challenges (nuclear entry, weaker human immunogenicity) with electroporation enhancement and veterinary success examples (equine West Nile). Panel D: Platform comparison table showing live attenuated (excellent immunity, immunocompromised contraindication), inactivated (safer, weaker, multiple doses), mRNA (rapid development, excellent efficacy, cold chain), viral vector (strong cellular immunity, pre-existing immunity concern), with heterologous prime-boost strategy combining platforms for enhanced immunity. </image>

IV. Adjuvants and Immune Enhancement

Adjuvants are substances added to vaccines to enhance the immune response to the target antigen, enabling stronger, more durable immunity with less antigen and fewer doses. The term derives from the Latin "adjuvare," meaning to help or aid. Adjuvants work through multiple mechanisms including creating a depot effect that prolongs antigen exposure, activating innate immune cells through pattern recognition receptor engagement, recruiting antigen-presenting cells to the injection site, promoting antigen uptake and processing, and enhancing costimulatory molecule expression to optimize T cell activation. The selection of adjuvant influences not only the magnitude but also the quality of the immune response, including Th1 versus Th2 polarization, IgG subclass distribution, and induction of cellular versus humoral immunity.

Aluminum salts (alum) have been the most widely used vaccine adjuvants since their introduction in the 1920s. Aluminum hydroxide and aluminum phosphate enhance antibody responses and have excellent safety records supported by decades of use. The mechanisms include depot formation, NLRP3 inflammasome activation, and induction of local inflammation that recruits and activates immune cells. Alum is used in numerous vaccines including DTaP, hepatitis B, hepatitis A, and pneumococcal conjugate vaccines. Oil-in-water emulsions represent another adjuvant class; MF59 (squalene-based) is used in some influenza vaccines, particularly for elderly populations who respond poorly to unadjuvanted vaccines. The AS01 adjuvant system, containing MPL (monophosphoryl lipid A, a TLR4 agonist) and QS-21 (a saponin), is used in the highly effective Shingrix zoster vaccine and produces particularly strong cellular immune responses. AS04, combining alum with MPL, is used in the hepatitis B vaccine Fendrix and some HPV vaccines.

Toll-like receptor (TLR) agonists have emerged as a promising class of adjuvants that activate specific innate immune pathways. MPL, a detoxified derivative of bacterial lipopolysaccharide, activates TLR4 and promotes Th1 responses. CpG oligodeoxynucleotides, which mimic bacterial DNA motifs, activate TLR9 in B cells and plasmacytoid dendritic cells; a CpG-adjuvanted hepatitis B vaccine (Heplisav-B) demonstrates superior immunogenicity with fewer doses compared to conventional alum-adjuvanted vaccines. These targeted adjuvants allow more precise tailoring of immune responses to match the protective mechanisms required for different pathogens.

Prime-boost vaccination strategies employ sequential immunizations with different vaccine platforms or formulations to optimize immune responses. Homologous prime-boost uses the same vaccine for all doses and is the standard approach for most vaccines. Heterologous prime-boost uses different platforms, potentially exploiting the unique strengths of each: for example, priming with a DNA or viral vector vaccine to establish strong T cell responses, followed by boosting with a protein subunit vaccine to enhance antibody responses. This approach has shown promise for difficult vaccine targets including HIV and malaria. During the COVID-19 pandemic, real-world evidence demonstrated that heterologous boosting (e.g., following adenoviral vector prime with mRNA boost) produced robust immune responses, sometimes exceeding those from homologous regimens. The scientific basis for heterologous prime-boost includes avoiding anti-vector immunity that may limit viral vector boosting and engaging distinct arms of the immune system with different platforms.

<image> Panel A: Adjuvant mechanisms diagram showing depot effect (antigen reservoir slowly releasing over time), innate immune activation through pattern recognition receptors (TLRs, NLRP3), APC recruitment to injection site by inflammatory signals, enhanced antigen uptake and processing by dendritic cells, and increased costimulation for optimal T cell activation. Panel B: Common adjuvants comparison showing aluminum salts (mechanism: depot + NLRP3, used in DTaP/HepB/PCV), MF59 squalene emulsion (enhanced influenza response in elderly), AS01 (MPL + QS-21, strong cellular immunity, used in Shingrix), AS04 (alum + MPL, used in Hep B and HPV vaccines), and CpG (TLR9 agonist, used in Heplisav-B). Panel C: TLR agonist adjuvants showing different TLRs in DC (TLR4 on surface recognizing MPL, TLR9 in endosome recognizing CpG), downstream signaling pathways, and resulting cytokine production (IL-12, type I IFN) shaping Th1-skewed adaptive immunity. Panel D: Prime-boost strategies comparison showing homologous (same vaccine repeated, standard approach), versus heterologous (different platforms, e.g., adenoviral prime then mRNA boost), with immune response graphs showing enhanced antibody and T cell responses from heterologous approach, and COVID-19 mixed regimen real-world evidence. </image>

V. Vaccine Development and Safety

Vaccine development proceeds through a rigorous multi-phase process designed to establish safety and efficacy before approval and widespread use. Preclinical studies evaluate candidate vaccines in laboratory settings and animal models, assessing immunogenicity (ability to induce immune responses), efficacy (protection against challenge in animal disease models when available), and preliminary safety. Phase 1 clinical trials are small studies (typically 10-100 participants) focused primarily on safety assessment in healthy volunteers, with secondary evaluation of immunogenicity and dose-ranging. Phase 2 trials expand to hundreds or sometimes thousands of participants to further evaluate safety, refine dosing, and confirm immunogenicity in the target population. Phase 3 trials are large-scale studies (often thousands to tens of thousands of participants) powered to demonstrate efficacy against the target disease, comparing outcomes in vaccinated versus placebo groups. These pivotal trials also provide a larger safety database to detect common adverse events.

Regulatory approval pathways vary by jurisdiction but follow similar principles. In the United States, vaccine manufacturers submit a Biologics License Application (BLA) to the FDA, containing comprehensive preclinical and clinical data demonstrating safety, purity, potency, and efficacy. The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviews the evidence and makes recommendations. Emergency Use Authorization (EUA) provides an expedited pathway during public health emergencies, requiring demonstration that benefits outweigh risks when no adequate alternatives exist; the COVID-19 vaccines were initially deployed under EUA before receiving full licensure. Following approval, the Advisory Committee on Immunization Practices (ACIP) provides recommendations on vaccine use, which are incorporated into the CDC immunization schedules. Post-marketing Phase 4 studies and surveillance continue to monitor safety and effectiveness in real-world conditions.

Robust vaccine safety monitoring systems detect adverse events that may not be apparent in clinical trials. The Vaccine Adverse Event Reporting System (VAERS) is a passive surveillance system that accepts reports of any adverse events following vaccination from healthcare providers, manufacturers, and the public; while it cannot establish causality, VAERS serves as an early warning system for potential safety signals. The Vaccine Safety Datalink (VSD) is an active surveillance system linking immunization records with medical records in several large healthcare organizations, enabling rapid epidemiological studies of potential adverse events. The Clinical Immunization Safety Assessment (CISA) Project provides clinical consultation for complex vaccine safety cases. Global coordination through the World Health Organization and its collaborating centers ensures international sharing of safety information. These layered systems successfully identified rare adverse events associated with COVID-19 vaccines, including myocarditis after mRNA vaccines and VITT after adenoviral vector vaccines, enabling risk communication and updated recommendations.

Addressing vaccine hesitancy and misinformation requires understanding and engaging with concerns rather than dismissing them. Common misconceptions include thoroughly disproven claims of associations between vaccines and autism (originating from a fraudulent, retracted study), concerns about "too many vaccines" overwhelming infants' immune systems (when in reality the antigen content of modern vaccines is far less than encountered daily from natural exposures), questions about ingredient safety (when vaccine components are present in minute quantities well below toxic thresholds), and beliefs that natural immunity is always superior (when vaccines provide protection without the risks of the actual disease). Effective communication acknowledges concerns, provides clear and accurate information, emphasizes the rigorous safety evaluation vaccines undergo, and highlights the diseases prevented by vaccination. Building trust requires transparency about what is known and unknown, prompt communication about adverse events when they occur, and engagement through trusted community sources.

<image> Panel A: Vaccine development phases showing preclinical (laboratory and animal studies, 2-4 years), Phase 1 (safety in 10-100 volunteers, months), Phase 2 (immunogenicity and dose in 100-1000 participants, 1-2 years), Phase 3 (efficacy in thousands, 2-4 years), regulatory review and approval, and post-marketing surveillance, with COVID-19 accelerated timeline comparison. Panel B: Regulatory pathway diagram showing manufacturer BLA submission to FDA, VRBPAC advisory committee review, FDA approval decision, ACIP recommendation development, CDC schedule incorporation, with parallel EUA emergency pathway shown for pandemic response. Panel C: Safety surveillance system layers showing VAERS (passive reporting, early signal detection), VSD (active surveillance in healthcare systems, rapid epidemiological studies), CISA (clinical consultation for complex cases), global WHO coordination, with example of COVID-19 vaccine safety signal detection (myocarditis, VITT) and response. Panel D: Vaccine hesitancy communication approach showing common misconceptions (autism link, immune overload, ingredient concerns, natural immunity superiority), evidence-based responses for each, and effective communication principles (acknowledge concerns, provide clear facts, emphasize safety evaluation, build trust through transparency). </image>

VI. Immunization Schedule and Special Populations

The childhood immunization schedule represents a carefully designed program to protect children against serious infectious diseases at the earliest ages when protection is needed and can be achieved. In the United States, the CDC and ACIP develop and annually update the schedule based on vaccine availability, disease epidemiology, and immunological considerations. The schedule begins at birth with hepatitis B vaccination, followed by doses at 2, 4, 6, and 12-18 months targeting diseases including diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, pneumococcal disease, and rotavirus. The MMR (measles, mumps, rubella) and varicella vaccines are administered at 12-15 months when maternal antibodies have waned sufficiently to allow response to live vaccines. Hepatitis A vaccination begins at 12 months. Booster doses at 4-6 years provide additional protection before school entry. At 11-12 years, adolescents receive Tdap, HPV vaccine (to prevent HPV-related cancers), and meningococcal conjugate vaccine. This schedule has dramatically reduced childhood morbidity and mortality from vaccine-preventable diseases.

Adult immunization addresses ongoing protection needs throughout life. Annual influenza vaccination is recommended for all adults, with specific formulations for older adults (high-dose, adjuvanted) who have diminished vaccine responses. Tdap is recommended once in adulthood, with Td boosters every 10 years thereafter. The two-dose Shingrix vaccine is recommended for adults 50 years and older to prevent herpes zoster and its complications, including postherpetic neuralgia. Pneumococcal vaccination is recommended for adults 65 and older and for younger adults with specific risk factors; current recommendations utilize PCV20 or sequential PCV15 followed by PPSV23. COVID-19 vaccination follows updated guidelines based on evolving variants and vaccine availability. Hepatitis B, HPV, and other vaccines are recommended for adults who were not previously vaccinated or who have specific risk factors.

Special populations require modified vaccination approaches based on their unique risks and immune status. Pregnant women should receive Tdap during each pregnancy (ideally between 27-36 weeks) to provide passive protection to newborns against pertussis, as well as influenza and COVID-19 vaccines; live vaccines are generally contraindicated during pregnancy due to theoretical fetal risks. Immunocompromised patients, including those with primary immunodeficiencies, HIV infection, transplant recipients, and those on immunosuppressive medications, should not receive live vaccines due to risk of vaccine-related disease; however, they may need additional doses of inactivated vaccines due to reduced responses. Asplenic patients are at high risk for encapsulated bacterial infections and should receive pneumococcal, Hib, and meningococcal vaccines. Healthcare workers have occupational risks and responsibilities to avoid transmitting infections to vulnerable patients, requiring hepatitis B, influenza, and other vaccines. Travelers may need additional vaccines depending on destination (yellow fever, typhoid, Japanese encephalitis, etc.).

Catch-up vaccination ensures that individuals who missed doses or are unvaccinated can achieve protection. The principle is that missed doses should be given as soon as feasible, with minimum intervals between doses respected but without restarting series. Catch-up schedules exist for children, adolescents, and adults with unknown or incomplete vaccination histories. For immigrants and refugees, vaccination records may be unavailable or unreliable; in such cases, age-appropriate vaccination should be administered according to catch-up schedules, or serological testing can document immunity for certain diseases. Catch-up vaccination is particularly important during disease outbreaks to rapidly increase community immunity. No individual is too old to begin or complete recommended vaccine series.

<image> Panel A: Childhood immunization schedule visual timeline showing vaccines by age from birth through adolescence: hepatitis B (birth), DTaP/IPV/Hib/PCV/RV (2, 4, 6 months), MMR/Varicella/Hep A (12-18 months), boosters (4-6 years), Tdap/HPV/MenACWY (11-12 years), with color-coded vaccine categories and disease icons. Panel B: Adult immunization recommendations showing annual influenza (all adults), Tdap once then Td every 10 years, Shingrix at age 50+ (two doses), pneumococcal at 65+, COVID-19 per current guidance, with conditional recommendations based on risk factors or prior vaccination status. Panel C: Special populations vaccination considerations showing pregnancy (Tdap each pregnancy, flu/COVID recommended, no live vaccines), immunocompromised (no live vaccines, may need additional doses), asplenia (encapsulated bacteria protection with pneumococcal/Hib/meningococcal), healthcare workers (HepB, flu, other occupational requirements), and travelers (destination-specific vaccines). Panel D: Catch-up vaccination principles showing missed doses administered with minimum intervals respected but series not restarted, example catch-up schedule for unvaccinated 7-year-old showing accelerated timeline, and approach for immigrants/refugees with unknown history (vaccinate per catch-up schedule or perform serologic testing). </image>

VII. Immunosuppressive Therapies

Corticosteroids remain the most widely used immunosuppressive agents due to their broad anti-inflammatory and immunomodulatory effects. Glucocorticoids (prednisone, prednisolone, methylprednisolone, dexamethasone) exert effects through genomic mechanisms, binding cytoplasmic glucocorticoid receptors that translocate to the nucleus and regulate transcription of numerous genes, suppressing pro-inflammatory cytokines while inducing anti-inflammatory mediators. Nongenomic effects include rapid membrane-mediated actions on cellular function. Corticosteroids reduce inflammation by suppressing cytokine production, inhibiting prostaglandin and leukotriene synthesis, decreasing vascular permeability, and inducing lymphocyte apoptosis. Clinical applications span autoimmune diseases, inflammatory conditions, allergic disorders, transplant rejection, and hematological malignancies. Adverse effects correlate with dose and duration and include hyperglycemia and diabetes, osteoporosis, adrenal suppression, weight gain, hypertension, cataracts, skin fragility, increased infection risk, and psychiatric effects. Steroid-sparing strategies aim to minimize these complications through use of alternative agents.

Antimetabolites interfere with nucleic acid synthesis to suppress lymphocyte proliferation. Methotrexate inhibits dihydrofolate reductase, depleting tetrahydrofolate required for purine and pyrimidine synthesis; at the low doses used in rheumatology, additional anti-inflammatory effects predominate, including adenosine release. Methotrexate is first-line therapy for rheumatoid arthritis and is used in psoriasis, inflammatory bowel disease, and various other autoimmune conditions. Adverse effects include hepatotoxicity, pneumonitis, bone marrow suppression, and teratogenicity. Azathioprine is metabolized to 6-mercaptopurine, which incorporates into DNA as a fraudulent nucleotide, inhibiting purine synthesis and causing DNA damage in proliferating cells. It is used in transplantation, autoimmune hepatitis, inflammatory bowel disease, and other conditions. Patients with thiopurine methyltransferase (TPMT) deficiency are at extreme risk for myelotoxicity and require dose reduction or alternative agents. Mycophenolate mofetil and mycophenolic acid inhibit inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo purine synthesis; lymphocytes are particularly dependent on this pathway, providing some selectivity. Mycophenolate is a cornerstone of transplant immunosuppression and is used in lupus nephritis and other autoimmune conditions.

Calcineurin inhibitors (cyclosporine and tacrolimus) block T cell activation by inhibiting the phosphatase calcineurin, preventing nuclear translocation of NFAT and subsequent transcription of IL-2 and other cytokines essential for T cell proliferation. Cyclosporine binds cyclophilin, while tacrolimus binds FKBP12; both drug-protein complexes inhibit calcineurin. These agents revolutionized organ transplantation and are also used in severe autoimmune diseases and dermatological conditions. Nephrotoxicity (both acute and chronic) is the major dose-limiting toxicity, alongside hypertension, neurotoxicity, diabetes (especially tacrolimus), and others. Therapeutic drug monitoring is essential due to narrow therapeutic indices and significant pharmacokinetic variability.

Additional immunosuppressive agents target specific pathways. mTOR inhibitors (sirolimus, everolimus) block cytokine-driven T cell proliferation at a stage downstream from calcineurin inhibitors and are used in transplantation and certain cancers. Cyclophosphamide, an alkylating agent that causes DNA crosslinking, is used in severe autoimmune diseases (lupus nephritis, ANCA-associated vasculitis) and malignancies despite significant toxicities including hemorrhagic cystitis and secondary malignancy risk. JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are oral small molecules that block Janus kinase signaling downstream of multiple cytokine receptors, approved for rheumatoid arthritis, inflammatory bowel disease, and atopic dermatitis; safety signals including infection, cardiovascular events, and malignancy require ongoing monitoring.

<image> Panel A: Corticosteroid mechanism showing glucocorticoid crossing cell membrane, binding cytoplasmic receptor, receptor-ligand complex translocating to nucleus, binding glucocorticoid response elements to suppress inflammatory gene transcription and induce anti-inflammatory genes; clinical uses (autoimmune, transplant, allergic) and dose-dependent adverse effects listed. Panel B: Antimetabolite mechanisms comparison showing methotrexate inhibiting DHFR (blocking folate pathway and purine synthesis), azathioprine metabolized to 6-MP incorporating into DNA as fraudulent nucleotide, and mycophenolate inhibiting IMPDH in de novo purine synthesis (lymphocyte selective), with indications and key toxicities for each. Panel C: Calcineurin inhibitor pathway showing T cell receptor signaling raising intracellular calcium, activating calcineurin to dephosphorylate NFAT, allowing nuclear translocation and IL-2 transcription; cyclosporine-cyclophilin and tacrolimus-FKBP12 complexes blocking calcineurin; nephrotoxicity mechanism and therapeutic drug monitoring requirement. Panel D: Other immunosuppressive agents showing mTOR inhibitor mechanism (blocking S6 kinase and cell cycle progression), cyclophosphamide DNA crosslinking, and JAK inhibitor blocking JAK-STAT cytokine signaling pathway, with indications and notable safety considerations for each. </image>

VIII. Biologic Therapies

Tumor necrosis factor (TNF) inhibitors represent a major advance in treating inflammatory diseases by targeting a key pro-inflammatory cytokine. TNF-alpha, produced primarily by activated macrophages and T cells, drives inflammation in rheumatoid arthritis, inflammatory bowel disease, psoriasis, and ankylosing spondylitis. Several TNF inhibitors are available with different structures: infliximab is a chimeric (mouse-human) monoclonal antibody binding soluble and membrane-bound TNF; adalimumab and golimumab are fully human monoclonal antibodies; etanercept is a soluble TNF receptor fusion protein (TNFR2-Fc) that acts as a decoy receptor; and certolizumab pegol is a PEGylated Fab fragment. These agents have transformed outcomes in inflammatory diseases, but increase susceptibility to infections, particularly tuberculosis reactivation (screening required before initiation), and carry warnings regarding lymphoma and other malignancies. Biosimilars (non-identical copies of biologic drugs demonstrating high similarity) are now available for several TNF inhibitors, improving access and reducing costs.

B cell-depleting and B cell-modulating therapies target pathogenic antibody production and other B cell functions. Rituximab, a chimeric anti-CD20 monoclonal antibody, depletes B cells through complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis induction. Originally developed for B cell lymphomas, rituximab is also used in rheumatoid arthritis, ANCA-associated vasculitis, and other autoimmune conditions. CD20 is not expressed on plasma cells, so existing antibody titers persist while new antibody production is suppressed. Ocrelizumab and ofatumumab are newer anti-CD20 antibodies used in multiple sclerosis. Belimumab targets BAFF (B cell activating factor), a cytokine essential for B cell survival, and is approved for systemic lupus erythematosus. Infusion reactions and increased infection risk are important considerations with B cell-targeted therapies.

IL-6 pathway inhibitors block a pleiotropic cytokine that drives inflammation, acute phase responses, and disease activity in rheumatoid arthritis and other conditions. Tocilizumab is a humanized anti-IL-6 receptor antibody that blocks IL-6 signaling; it is approved for rheumatoid arthritis, giant cell arteritis, and (critically) cytokine release syndrome associated with CAR-T therapy. Sarilumab is another IL-6 receptor antagonist for rheumatoid arthritis. Siltuximab directly binds IL-6 and is used in multicentric Castleman disease. Because IL-6 drives acute phase responses including C-reactive protein (CRP), IL-6 inhibitors can mask infection by suppressing fever and CRP elevation; vigilance for infection is essential during treatment.

Additional biologic therapies target other cytokines and immune pathways. IL-1 inhibitors (anakinra, canakinumab, rilonacept) are used in autoinflammatory diseases including systemic juvenile idiopathic arthritis, adult-onset Still disease, and cryopyrin-associated periodic syndromes. IL-12/23 inhibitors (ustekinumab) bind the shared p40 subunit of these cytokines and are used in psoriasis and inflammatory bowel disease. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) target the Th17 pathway and are highly effective in psoriasis and psoriatic arthritis. IL-23 inhibitors (risankizumab, guselkumab, tildrakizumab) selectively block IL-23 and are used in psoriasis and inflammatory bowel disease. IL-4/IL-13 inhibitors (dupilumab) block the shared IL-4 receptor alpha subunit involved in Th2 responses and are used in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The expanding array of targeted biologics enables increasingly personalized approaches to inflammatory and autoimmune diseases.

<image> Panel A: TNF inhibitor structures and mechanisms showing TNF-alpha as target cytokine, with different formats: infliximab (chimeric mAb), adalimumab (human mAb), etanercept (TNFR2-Fc fusion acting as decoy receptor), certolizumab (PEGylated Fab); clinical indications (RA, IBD, psoriasis, AS) with TB screening requirement and infection risk warnings. Panel B: B cell-targeted therapies showing rituximab binding CD20 on B cell surface, causing depletion via complement, ADCC, and apoptosis, with indication that plasma cells lack CD20 so existing antibodies persist; ocrelizumab for MS; belimumab blocking BAFF to reduce B cell survival; indications and infusion reaction considerations. Panel C: IL-6 pathway blockade showing IL-6 binding IL-6R and gp130, activating JAK-STAT signaling with pleiotropic effects (acute phase response, inflammation, fever); tocilizumab blocking IL-6R, used in RA, GCA, and CRS; warning that IL-6 blockade masks infection signs by suppressing fever and CRP. Panel D: Other cytokine-targeted biologics showing IL-1 pathway inhibitors (anakinra, canakinumab for autoinflammatory), IL-12/23p40 inhibitor (ustekinumab), IL-17 inhibitors (secukinumab for psoriasis), IL-23 selective inhibitors (risankizumab), IL-4/13 inhibitor (dupilumab for atopic disease), each with mechanism diagram and key indications. </image>

IX. Cytokine and Immunostimulatory Therapies

Interferons are cytokines with antiviral, antiproliferative, and immunomodulatory properties that have been developed as therapeutics for various conditions. Interferon-alpha (IFN-alpha), produced naturally by plasmacytoid dendritic cells in response to viral infection, was historically used to treat chronic hepatitis B and C (largely replaced by direct-acting antivirals) and remains approved for certain hematological malignancies and as adjuvant therapy for high-risk melanoma. Interferon-beta (IFN-beta), produced by fibroblasts and other cells, is used to reduce relapse rates and disease progression in multiple sclerosis; its mechanisms include immunomodulatory effects that shift the balance away from pro-inflammatory Th1 and Th17 responses. Interferon-gamma (IFN-gamma), produced by Th1 cells and NK cells, activates macrophages and is used to reduce serious infections in chronic granulomatous disease (CGD), where phagocyte oxidative burst is defective. Adverse effects of interferons include flu-like symptoms (fever, myalgias, fatigue), depression, cytopenias, and autoimmune phenomena.

Interleukins used therapeutically are limited compared to the broad range identified in immunology. High-dose interleukin-2 (IL-2, aldesleukin) activates T cells and NK cells and achieved durable complete responses in a small percentage of patients with metastatic melanoma and renal cell carcinoma, representing one of the earliest effective cancer immunotherapies. However, severe toxicity including capillary leak syndrome, hypotension, and multiorgan dysfunction limits its use and requires administration in specialized ICU-capable settings. IL-2 has largely been superseded by checkpoint inhibitors but informed the development of next-generation IL-2 variants engineered for improved selectivity. Oprelvekin (IL-11) stimulates platelet production and was used for chemotherapy-induced thrombocytopenia but has been largely replaced by thrombopoietin receptor agonists.

Colony-stimulating factors (CSFs) stimulate the production and function of specific hematopoietic lineages and have important roles in managing cytopenias. Granulocyte colony-stimulating factor (G-CSF, filgrastim, pegfilgrastim) stimulates neutrophil production and is used to treat or prevent neutropenia, particularly chemotherapy-induced neutropenia, and to mobilize hematopoietic stem cells from bone marrow to peripheral blood for collection before stem cell transplantation. Granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) has broader effects on myeloid lineages and is used for bone marrow recovery after transplantation. Erythropoiesis-stimulating agents (erythropoietin, darbepoetin) stimulate red blood cell production and are used in anemia of chronic kidney disease and chemotherapy-induced anemia, with attention to target hemoglobin levels and thrombotic risks. Thrombopoietin receptor agonists (romiplostim, eltrombopag, avatrombopag) stimulate platelet production and are used in immune thrombocytopenia and aplastic anemia.

Intravenous immunoglobulin (IVIG) provides pooled human IgG from thousands of donors and serves both replacement and immunomodulatory functions. Replacement therapy in primary antibody deficiencies and secondary hypogammaglobulinemia provides passive protection against infections. High-dose IVIG has immunomodulatory effects used in autoimmune and inflammatory conditions including immune thrombocytopenic purpura (ITP), Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), Kawasaki disease, and dermatomyositis. Mechanisms of immunomodulatory IVIG may include Fc receptor blockade on phagocytes, anti-idiotype antibodies that neutralize pathogenic autoantibodies, complement inhibition, and regulatory effects on immune cells. Subcutaneous immunoglobulin (SCIG) provides an alternative route for replacement therapy, enabling home administration. Specific (hyperimmune) immunoglobulins contain high titers of antibodies against particular pathogens and are used for post-exposure prophylaxis against hepatitis B, varicella, tetanus, rabies, and other infections.

<image> Panel A: Interferon therapeutic uses showing IFN-alpha (historical HCV/HBV treatment, melanoma adjuvant), IFN-beta (multiple sclerosis immunomodulation), and IFN-gamma (CGD infection prophylaxis by enhancing macrophage function), with mechanisms illustrated and common adverse effects (flu-like symptoms, depression, cytopenias) listed. Panel B: IL-2 high-dose therapy showing T cell and NK cell activation, anti-tumor efficacy in melanoma and RCC subset, with capillary leak syndrome pathophysiology (IL-2 induced endothelial changes causing fluid extravasation, hypotension, organ dysfunction) and next-generation engineered IL-2 variants concept. Panel C: Colony-stimulating factors diagram showing G-CSF stimulating neutrophil production in bone marrow and peripheral mobilization of stem cells, GM-CSF broader myeloid effects, erythropoietin-stimulating RBC production, and TPO receptor agonists stimulating megakaryopoiesis and platelet production, with clinical indications for each. Panel D: IVIG mechanisms and uses showing replacement therapy for antibody deficiency (passive IgG providing infection protection), and high-dose immunomodulatory uses (ITP, GBS, CIDP, Kawasaki) with proposed mechanisms (Fc receptor blockade, anti-idiotype antibodies, complement inhibition), plus SCIG and hyperimmune globulin products for specific pathogens. </image>

X. Adverse Reactions and Special Considerations

Vaccine adverse reactions range from common and expected responses reflecting immune activation to rare but serious events requiring surveillance and management. Local reactions at the injection site, including pain, erythema, and swelling, occur in a substantial proportion of vaccine recipients and reflect the inflammatory response to the injected material; these are self-limited and do not contraindicate further vaccination. Systemic reactions including fever, fatigue, myalgias, and malaise represent the effects of inflammatory cytokines and are more common with more immunogenic vaccines and adjuvants. These expected reactions are generally mild to moderate and resolve within days. Allergic reactions, including urticaria and rarely anaphylaxis, can occur in response to vaccine components; anaphylaxis occurs at a rate of approximately 1 per million doses for most vaccines, though rates vary by product. Rare serious adverse events, including Guillain-Barre syndrome following certain influenza vaccines, thrombocytopenia after MMR, and myocarditis after mRNA COVID-19 vaccines (particularly in young males), require ongoing surveillance to characterize risk and inform benefit-risk assessments.

Biologic therapies carry important adverse effect profiles that require monitoring and management. Increased infection risk is universal among immunosuppressive biologics, with particular concerns for tuberculosis reactivation with TNF inhibitors (requiring screening and treatment of latent TB before initiation), progressive multifocal leukoencephalopathy (PML) with certain agents (natalizumab), and opportunistic infections generally. Infusion reactions occur with intravenously administered biologics, ranging from mild symptoms managed with premedication and rate adjustment to severe anaphylaxis requiring treatment discontinuation. Paradoxical reactions, where biologics induce the very conditions they are used to treat (e.g., TNF inhibitor-induced psoriasis, demyelinating disease, or lupus-like syndrome), are recognized phenomena requiring awareness. Long-term safety concerns include malignancy risk (particularly lymphoma with TNF inhibitors, though the absolute risk increase is small), cardiovascular events with certain JAK inhibitors, and autoimmune phenomena including drug-induced lupus and autoantibody formation.

Contraindications to vaccines and biologics require careful assessment in clinical practice. True contraindications are conditions that increase the risk of serious adverse reaction and preclude administration. For vaccines, severe allergic reaction to a vaccine component or previous dose is a contraindication; moderate or severe acute illness is a precaution warranting deferral until recovery. Live vaccines are contraindicated in immunocompromised individuals and during pregnancy. For most biologics, active serious infection is a contraindication. Specific contraindications exist for individual agents based on their mechanisms and known risks.

Future directions in vaccinology and immunotherapy promise continued advances in prevention and treatment of disease. Universal influenza vaccines targeting conserved epitopes could provide broad, durable protection without annual reformulation. Effective HIV vaccines remain elusive but continue to be pursued through novel approaches. Malaria vaccines have recently achieved milestones, with the RTS,S and R21/Matrix-M vaccines receiving WHO recommendations. Therapeutic vaccines for cancer and chronic infections aim to harness the immune system against established disease. The mRNA platform developed for COVID-19 is being applied to other infectious diseases and potentially personalized cancer vaccines. Advances in understanding of immunological mechanisms will enable more targeted modulation of immune responses for both prevention and treatment, bringing the promise of personalized immunotherapy closer to reality.

<image> Panel A: Vaccine adverse reaction spectrum showing local reactions (pain, erythema, swelling at site - common, self-limited), systemic reactions (fever, fatigue, myalgias - reflecting cytokine response), allergic reactions (urticaria to anaphylaxis - rare, ~1/million), and rare serious events (GBS, myocarditis - detected by surveillance), with management approach for each. Panel B: Biologic therapy adverse effects showing infection risk (TB screening chest X-ray, opportunistic infections), infusion reactions (management with premedication, rate reduction), paradoxical reactions (TNF inhibitor-induced psoriasis example), and long-term concerns (lymphoma, cardiovascular events, autoimmunity), with monitoring recommendations. Panel C: Contraindications assessment showing vaccine contraindications (severe allergy to component, immunocompromised for live vaccines, pregnancy for live vaccines) versus precautions (acute illness warranting deferral), and biologic contraindications (active serious infection, specific agent warnings), with clinical decision flowchart. Panel D: Future directions showing universal influenza vaccine concept (targeting conserved hemagglutinin stalk), ongoing HIV vaccine research strategies, malaria vaccine milestones (RTS,S and R21/Matrix-M), mRNA platform expansion to other diseases, and personalized cancer vaccine pipeline, representing the expanding immunotherapy frontier. </image>

Summary

• Vaccination induces immunological memory, enabling rapid and effective secondary responses upon pathogen exposure; herd immunity protects unvaccinated individuals when sufficient population immunity interrupts transmission
• Live attenuated vaccines provide potent, durable immunity but are contraindicated in immunocompromised individuals; inactivated and subunit vaccines are safer but typically less immunogenic
• mRNA vaccines enable rapid development and produce excellent immune responses; viral vector vaccines induce strong cellular immunity but face pre-existing immunity and rare safety concerns
• Adjuvants enhance vaccine immunogenicity through depot effects, innate immune activation, and APC recruitment; prime-boost strategies can optimize immune responses
• Vaccine development proceeds through preclinical, Phase 1-3 clinical trials, and post-marketing surveillance; safety monitoring systems (VAERS, VSD) detect rare adverse events
• Immunization schedules are tailored for different ages and populations; special considerations apply to pregnancy, immunocompromised patients, and travelers
• Immunosuppressive therapies (corticosteroids, antimetabolites, calcineurin inhibitors) target various steps in immune activation and are used in autoimmune diseases and transplantation
• Biologic therapies (anti-TNF, B cell-targeting, IL-6 inhibitors, other cytokine blockers) provide targeted immunomodulation with specific efficacy and safety profiles
• Colony-stimulating factors support hematopoiesis, while IVIG serves replacement and immunomodulatory functions
• Adverse reactions to vaccines and biologics require monitoring and management; contraindications must be assessed before administration

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown